Enveric Biosciences Secures Second USPTO Notice of Allowance for EVM401 Series

Enveric Biosciences (ENVB) received a second notice of allowance from the USPTO for its EVM401 Series, expanding its intellectual property assets in treating mental health disorders. The allowed patent application covers novel compounds that are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders.

Enveric Biosciences (ENVB) has received a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent application, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," covers a unique series of methylone-inspired compounds that are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders [1].

The patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care [2]. Enveric's molecules share pharmacophoric elements with methylone but differ structurally in ways that render them patentable and proprietary, unlike methylone, which lacks available composition of matter patent exclusivity due to its public domain structure.

The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment [2]. Further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints.

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates [2]. The company is headquartered in Naples, FL, with offices in Cambridge, MA, and Calgary, AB, Canada.

References:
[1] https://www.biospace.com/press-releases/enveric-biosciences-secures-second-u-s-patent-allowance-for-next-generation-non-hallucinogenic-mescaline-derivatives-in-evm401-series
[2] https://www.enveric.com/news/enveric-biosciences-secures-second-u-s-patent-allowance-for-next-generation-non-hallucinogenic-mescaline-derivatives-in-evm401-series/